N/A N=436 Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Patent Ductus Arteriosus (PDA)
Primary: Reporting of Late Adverse Events Relating to the Device. — 9 participant
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=72 Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
Epilepsy
Primary: Number of Subjects With Reported Adverse Events (AE) — 3; 3; 11; 10 participants
N/A N=24 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
Ureteral Obstruction
Primary: Mean Stent Dwell Time — 17; 3.97 months
Phase 1 N=10 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
Neuromyelitis Optica
Primary: Number of Adverse Safety Events During Hospitalization — 0 adverse safety events
Phase 3 N=895 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Phase: Percentage of Participants With a Clinical Response at Week 6 — 25.5; 47.1 percentage of participants — p=< 0.0001
Phase 2 N=50 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Phase 3 N=196 Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
Major Depressive Disorder
Primary: Score on a Depression Severity Rating Scale Over Eight Weeks — -10.34; -9.26; -9.49 units on a scale
Phase 2 N=21 Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Adenocarcinoma of the Stomach · Recurrent Gastric Cancer
Primary: Objective Tumor Response (Defined as Partial [PR] or Complete Response [CR] by RECIST Criteria) — 0 participants
Phase 2 N=47 Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Adverse Events — 7; 9; 9; 6 participants
Phase 3 N=105 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Leukemia
Primary: 3-year Disease-free Survival (DFS) Rate — 96; 100 percentage of patients
Phase 3 N=556 A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
Rheumatoid Arthritis
Primary: Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24 — 40.4; 34.8 Percentage of participants — p=0.2055
N/A N=34 Pilot Study of B-Type Natrieutic Peptide (BNP) Levels in Patients With Congenital Heart Disease(BNP)
Congenital Heart Disease · Cardiovascular Disease
Primary: BNP Levels — 16.3; 42.4; 384.3 pg/ml
Phase 3 N=304 Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
Partial Epilepsy in Children and Adolescents
Primary: Change From Baseline in Seizure Frequency — 62.0; 36.6 seizures/month — p=0.2490
Phase 4 N=306 Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
Active Rheumatoid Arthritis · Arthritis, Rheumatoid · Rheumatoid Arthritis
Primary: Number of Participants That Met Sustained Remission at Week 76 and Week 91 Based on DAS28 Score — 40; 26; 15 Participants — p=<0.0001
N/A N=48 Hemodynamic Effects of Standard Cardiopulmonary Resuscitation (CPR), Active Compression Decompression CPR With an Inspiratory Impedance Device, and Standard CPR With an Intrathoracic Pressure Regulator During Out-of-hospital Cardiac Arrest
Cardiac Arrest · Sudden Cardiac Death
Primary: Mean Systolic and Diastolic Blood Pressures — 80.38; 121.21; 61.37; 15.52 mmHg